| 3 | 1/1 | 返回列表 |
| 查看: 478 | 回復(fù): 2 | ||
2010020170金蟲 (小有名氣)
|
[交流]
【求助】氯雷他定片 國外標(biāo)準(zhǔn) 已有2人參與
|
| 有誰知道 氯雷他定片的國外標(biāo)準(zhǔn) 我不知道在哪可以查到 謝謝 |

金蟲 (正式寫手)
海闊天空
|
USP32-NF27收載過。 Loratadine Tablets » Loratadine Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of loratadine (C22H23ClN2O2). Packaging and storage— Preserve in tight containers, and store between 2 and 30. Protect from excessive moisture if packaged in blisters. USP Reference standards 11— USP Loratadine RS . Identification— A: Thin-Layer Chromatographic Identification Test 201— Test solution— Transfer an accurately weighed quantity of Tablets, equivalent to about 20 mg of loratadine, to a centrifuge tube. Add 5.0 mL of a mixture of chloroform and methanol (1:1), rotate for 30 minutes, and centrifuge. Standard solution— Dissolve an accurately weighed quantity of about 20 mg of USP Loratadine RS in 5 mL of a mixture of chloroform and methanol (1:1), and mix. Application volume: 5 µL. Developing solvent system: ethyl ether and diethylamine (40:1), in a paper-lined tank. B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay. Dissolution 711— Medium: 0.1 N hydrochloric acid; 900 mL. Apparatus 2: 50 rpm. Time: 60 minutes. Procedure— Determine the amount of C22H23ClN2O2 dissolved from UV absorption at the wavelength of maximum absorbance at about 280 nm on filtered portions of the solution under test, suitably diluted with Dissolution Medium, if necessary, in comparison with a Standard solution having a known concentration of USP Loratadine RS in the same Medium. Tolerances— Not less than 80% (Q) of the labeled amount of C22H23ClN2O2 is dissolved in 60 minutes. Uniformity of dosage units 905: meet the requirements. Related compounds— 0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, and Diluent— Proceed as directed in the Assay under Loratadine. Standard stock solution— Prepare as directed for Standard preparation in the Assay under Loratadine. Standard solution— Pipet 5.0 mL of the Standard stock solution into a 100-mL volumetric flask, and dilute with Diluent to volume. Dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.8 µg per mL. Test solution— Use the Assay preparation. Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L7. The flow rate is about 1 mL per minute. Chromatograph the Test solution, and record the peak areas as directed for Procedure: the relative retention times are about 0.79 for 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl and 1.0 for loratadine. Chromatograph the Standard solution, and record the peak areas of the main peak as directed for Procedure: the relative standard deviation for replicate injections is not more than 4.0%. Procedure— Separately inject equal volumes (about 50 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure all of the peak area responses in the Test solution and the peak area of the main peak in the Standard solution. Calculate the percentage of each impurity in the portion of Tablets taken by the formula: 2500(C/L)(ri / rS) in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard solution; L is the labeled quantity, in mg, of loratadine in each Tablet taken; ri is the peak area response for each impurity in the Test solution; and rS is the peak area response of loratadine in the Standard solution: not more than 0.2% of 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl is found; not more than 0.1% of any other individual impurity is found; and the sum of all impurities, other than 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl, is not more than 0.1%. Assay— 0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, Diluent, and Standard preparation— Proceed as directed in the Assay under Loratadine. Assay preparation— Transfer 10 Tablets into a 250-mL volumetric flask, add 100 mL of 0.05 N Hydrochloric acid, and shake for 40 minutes or until the Tablets are completely disintegrated. Add 75 mL of a mixture of methanol and acetonitrile (1:1), and mix. Add 20 mL of 0.6 M Dibasic potassium phosphate, and mix for 5 minutes. Dilute with a mixture of methanol and acetonitrile (1:1) to volume, and mix. Chromatographic system (see Chromatography 621)— Prepare as directed in the Assay under Loratadine. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 3.5; the tailing factor is not more than 1.7; and the relative standard deviation for replicate injections is not more than 2.0%. Procedure— Separately inject equal volumes (about 15 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak response for the major peaks. Calculate the quantity, in mg, of loratadine (C22H23ClN2O2) in the portion of Tablets taken by the formula: 250C(rU / rS) in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively. Auxiliary Information— Please check for your question in the FAQs before contacting USP. Topic/Question Contact Expert Committee Monograph Daniel K. Bempong, Ph.D. Senior Scientist 1-301-816-8143 (MDPS05) Monograph Development-Pulmonary and Steroids Reference Standards Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org 711 Margareth R.C. Marques, Ph.D. Senior Scientist 1-301-816-8106 (BPC05) Biopharmaceutics05 USP32–NF27 Page 2808 Pharmacopeial Forum: Volume No. 29(4) Page 1045 Chromatographic Column— LORATADINE TABLETS Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27. |

金蟲 (小有名氣)

| 3 | 1/1 | 返回列表 |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
百度網(wǎng)盤 |
360云盤 |
千易網(wǎng)盤 |
華為網(wǎng)盤
在新窗口頁面中打開自己喜歡的網(wǎng)盤網(wǎng)站,將文件上傳后,然后將下載鏈接復(fù)制到帖子內(nèi)容中就可以了。 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿華中科技大學(xué)071000,求調(diào)劑 +3 | 沿岸有貝殼6 2026-03-21 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 346求調(diào)劑[0856] +4 | WayneLim327 2026-03-16 | 7/350 |
|
|
[考研] 265求調(diào)劑 +9 | 梁梁校校 2026-03-17 | 9/450 |
|
|
[考研] 華東師范大學(xué)-071000生物學(xué)-293分-求調(diào)劑 +3 | 研究生何瑤明 2026-03-18 | 3/150 |
|
|
[考研] 280求調(diào)劑 +7 | 咕嚕曉曉 2026-03-18 | 8/400 |
|
|
[考研] 一志愿武理材料305分求調(diào)劑 +6 | 想上岸的鯉魚 2026-03-18 | 7/350 |
|
|
[考研] 一志愿 西北大學(xué) ,070300化學(xué)學(xué)碩,總分287,雙非一本,求調(diào)劑。 +3 | 晨昏線與星海 2026-03-18 | 3/150 |
|
|
[考研] 材料專業(yè)求調(diào)劑 +6 | hanamiko 2026-03-18 | 6/300 |
|
|
[考研] 321求調(diào)劑 +9 | 何潤采123 2026-03-18 | 11/550 |
|
|
[考研] 藥學(xué)383 求調(diào)劑 +3 | 藥學(xué)chy 2026-03-15 | 5/250 |
|
|
[考研] A區(qū)線材料學(xué)調(diào)劑 +5 | 周周無極 2026-03-20 | 5/250 |
|
|
[考研]
|
簡木ChuFront 2026-03-19 | 8/400 |
|
|
[基金申請]
學(xué)校已經(jīng)提交到NSFC,還能修改嗎?
40+4
|
babangida 2026-03-19 | 8/400 |
|
|
[論文投稿]
申請回稿延期一個月,編輯同意了。但系統(tǒng)上的時間沒變,給編輯又寫郵件了,沒回復(fù)
10+3
|
wangf9518 2026-03-17 | 4/200 |
|
|
[考研] 化學(xué)工程321分求調(diào)劑 +15 | 大米飯! 2026-03-15 | 18/900 |
|
|
[考研] 312求調(diào)劑 +8 | 陌宸希 2026-03-16 | 9/450 |
|
|
[考研] 293求調(diào)劑 +11 | zjl的號 2026-03-16 | 16/800 |
|
|
[考研] 302求調(diào)劑 +4 | 小賈同學(xué)123 2026-03-15 | 8/400 |
|
|
[考研] 277材料科學(xué)與工程080500求調(diào)劑 +3 | 自由煎餅果子 2026-03-16 | 3/150 |
|
|
[考研] 26考研一志愿中國石油大學(xué)(華東)305分求調(diào)劑 +3 | 嘉年新程 2026-03-15 | 3/150 |
|